SV2018005733A - Procedimientos para el tratamiento y la profilaxis de vih y sida - Google Patents

Procedimientos para el tratamiento y la profilaxis de vih y sida

Info

Publication number
SV2018005733A
SV2018005733A SV2018005733A SV2018005733A SV2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A SV 2018005733 A SV2018005733 A SV 2018005733A
Authority
SV
El Salvador
Prior art keywords
treatment
hiv
aids
procedures
prophylaxis
Prior art date
Application number
SV2018005733A
Other languages
English (en)
Spanish (es)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
-Griffith Deborah Anne Nicoli
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2018005733A publication Critical patent/SV2018005733A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
SV2018005733A 2016-02-12 2018-08-09 Procedimientos para el tratamiento y la profilaxis de vih y sida SV2018005733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19

Publications (1)

Publication Number Publication Date
SV2018005733A true SV2018005733A (es) 2018-12-14

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005733A SV2018005733A (es) 2016-02-12 2018-08-09 Procedimientos para el tratamiento y la profilaxis de vih y sida

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX2022002925A (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI822652B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
EP3823632B1 (en) 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122576C (en) * 2018-12-20 2025-11-25 Merck Sharp & Dohme Llc CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权(第2 号)有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
CN102174038A (zh) 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
WO2017222903A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
AU2021268584A1 (en) * 2020-05-05 2022-12-01 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
IL260874A (https=) 2018-09-20
KR20210049201A (ko) 2021-05-04
US20200101098A1 (en) 2020-04-02
JP2021001189A (ja) 2021-01-07
MY197090A (en) 2023-05-24
JP2024001206A (ja) 2024-01-09
IL260874B2 (en) 2023-10-01
UA126375C2 (uk) 2022-09-28
JP6810972B2 (ja) 2021-01-13
AU2017217656A1 (en) 2018-08-23
KR20250136420A (ko) 2025-09-16
TW202417010A (zh) 2024-05-01
CN113509480A (zh) 2021-10-19
RS64448B1 (sr) 2023-09-29
FI3413897T3 (fi) 2023-08-25
EA201891814A1 (ru) 2019-01-31
HK1257347A1 (en) 2019-10-18
PL3413897T3 (pl) 2023-10-02
GEP20207190B (en) 2020-12-10
MX2022002924A (es) 2022-12-15
JP7559175B2 (ja) 2024-10-01
NZ784982A (en) 2025-03-28
AU2020202866B2 (en) 2022-04-07
ZA201805073B (en) 2019-05-29
TW201731514A (zh) 2017-09-16
DOP2018000183A (es) 2018-12-31
WO2017139519A1 (en) 2017-08-17
GEAP202014873A (en) 2020-07-27
HRP20230935T1 (hr) 2023-11-24
AU2022201686A1 (en) 2022-03-31
MX390604B (es) 2025-03-20
PT3413897T (pt) 2023-08-28
CA3013473A1 (en) 2017-08-17
CN108697727A (zh) 2018-10-23
AU2022201686B2 (en) 2024-08-08
US12171776B2 (en) 2024-12-24
JP7021314B2 (ja) 2022-02-16
MD3413897T2 (ro) 2023-11-30
KR102317570B1 (ko) 2021-10-25
TN2018000267A1 (en) 2020-01-16
MX2022002925A (es) 2023-02-10
JOP20170038B1 (ar) 2021-08-17
HUE063532T2 (hu) 2024-01-28
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
BR112018016349A2 (pt) 2018-12-26
ES2953535T3 (es) 2023-11-14
SG11201806783WA (en) 2018-09-27
GEP20217231B (en) 2021-03-25
NI201800083A (es) 2018-10-05
EP3413897B1 (en) 2023-06-14
NZ745065A (en) 2023-11-24
AU2020202866A1 (en) 2020-05-21
PH12018501712A1 (en) 2019-05-15
JP2022062170A (ja) 2022-04-19
EP3413897A1 (en) 2018-12-19
CA3013473C (en) 2021-10-26
TWI911551B (zh) 2026-01-11
US11337991B2 (en) 2022-05-24
IL260874B1 (en) 2023-06-01
KR20180108815A (ko) 2018-10-04
SI3413897T1 (sl) 2023-11-30
MX2018009763A (es) 2018-11-29
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
US20220331350A1 (en) 2022-10-20
JP2019504857A (ja) 2019-02-21
LT3413897T (lt) 2023-08-25
DK3413897T3 (da) 2023-09-18
AU2017217656B2 (en) 2020-01-30
US20250073254A1 (en) 2025-03-06
KR20220126787A (ko) 2022-09-16
TWI822652B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
SV2018005733A (es) Procedimientos para el tratamiento y la profilaxis de vih y sida
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
MX391226B (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
SV2009003294A (es) Inhibidores de transcriptasa inversa no nucleosidicos
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
MX2024013042A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
AR107596A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida
HK40061663A (en) Combination treatment of hiv infections